secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001193125-26-019536
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share
-------------------------------------------------------------------------------

- 5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.
- Underwriters have 30-day option to purchase up to 884,615 additional shares.
- Proceeds to fund BGE-102, NLRP3, and APJ programs, plus working capital and debt reduction.
- Goldman Sachs, Piper Sandler, and Citigroup are joint book-running managers.
- Offering expected to close on January 23, 2026, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/bioa-20260121.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-019536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer